fda pulling semaglutide Oral Gets Approval for CV Event Reduction in High-risk Diabetes Patients Novo asks FDA to bar

Since 2024, we've worked with @EliLillyandCo to expand access to FDA-approved GLP-1s, and this is another step toward making treatment simpler and more seamless for patients

Are you on a GLP-1? Studies show up to 40% of weight lost on GLP-1 medications may come from lean body mass, including muscle

Findings from a recent study are providing support for the combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to optimize cardiovascular and kidney outcomes in patients with diabetes

refrigerate after reconstitution and use within 30 days

Results Oral semaglutide was safe and well-tolerated in both trials

Thousands and thousands of known compounds were individually added to these cells using robotics and whether they had any influence on the receptors was detected